Sacituzumab Govitecan Succeeds in Phase III TNBC Trial as FDA Weighs Approval

Sacituzumab Govitecan Succeeds in Phase III TNBC Trial, as FDA Weighs Approval

Positive efficacy data have halted  the confirmatory phase III ASCENT study exploring sacituzumab govitecan in patients with metastatic triple-negative breast cancer.

More From BioPortfolio on "Sacituzumab Govitecan Succeeds in Phase III TNBC Trial, as FDA Weighs Approval"